vs

Side-by-side financial comparison of AST SpaceMobile, Inc. (ASTS) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.

SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $54.3M, roughly 1.2× AST SpaceMobile, Inc.). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs -136.2%, a 175.6% gap on every dollar of revenue. SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $-330.7M).

AST SpaceMobile, Inc. is a publicly traded satellite designer and manufacturer based in Midland, Texas, United States. The company is building the SpaceMobile satellite constellation, a space-based cellular broadband network designed to connect directly to standard, unmodified smartphones. The network is intended to deliver 4G and 5G broadband coverage globally, particularly in remote and underserved regions.

SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.

ASTS vs SLNO — Head-to-Head

Bigger by revenue
SLNO
SLNO
1.2× larger
SLNO
$66.0M
$54.3M
ASTS
Higher net margin
SLNO
SLNO
175.6% more per $
SLNO
39.4%
-136.2%
ASTS
More free cash flow
SLNO
SLNO
$374.2M more FCF
SLNO
$43.5M
$-330.7M
ASTS

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ASTS
ASTS
SLNO
SLNO
Revenue
$54.3M
$66.0M
Net Profit
$-74.0M
$26.0M
Gross Margin
98.3%
Operating Margin
-175.0%
33.5%
Net Margin
-136.2%
39.4%
Revenue YoY
2758.2%
Net Profit YoY
-106.3%
134.0%
EPS (diluted)
$0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTS
ASTS
SLNO
SLNO
Q4 25
$54.3M
Q3 25
$14.7M
$66.0M
Q2 25
$32.7M
Q4 23
$0
Q3 23
$0
Q2 23
$0
Q4 22
$-1.0K
Q2 22
$7.3M
Net Profit
ASTS
ASTS
SLNO
SLNO
Q4 25
$-74.0M
Q3 25
$-122.9M
$26.0M
Q2 25
$-4.7M
Q4 23
$-31.9M
Q3 23
$-20.9M
Q2 23
$-18.4M
Q4 22
$-8.2M
Q2 22
$-2.9M
Gross Margin
ASTS
ASTS
SLNO
SLNO
Q4 25
Q3 25
98.3%
Q2 25
97.9%
Q4 23
Q3 23
Q2 23
Q4 22
200.0%
Q2 22
69.7%
Operating Margin
ASTS
ASTS
SLNO
SLNO
Q4 25
-175.0%
Q3 25
-1109.0%
33.5%
Q2 25
-20.0%
Q4 23
Q3 23
Q2 23
Q4 22
2522300.0%
Q2 22
-109.7%
Net Margin
ASTS
ASTS
SLNO
SLNO
Q4 25
-136.2%
Q3 25
-833.7%
39.4%
Q2 25
-14.4%
Q4 23
Q3 23
Q2 23
Q4 22
822900.0%
Q2 22
-40.3%
EPS (diluted)
ASTS
ASTS
SLNO
SLNO
Q4 25
Q3 25
$0.47
Q2 25
$-0.09
Q4 23
Q3 23
Q2 23
Q4 22
Q2 22
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTS
ASTS
SLNO
SLNO
Cash + ST InvestmentsLiquidity on hand
$4.3B
$498.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.4B
$494.8M
Total Assets
$5.0B
$599.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTS
ASTS
SLNO
SLNO
Q4 25
$4.3B
Q3 25
$2.4B
$498.9M
Q2 25
$286.8M
Q4 23
$155.3M
Q3 23
$251.7M
Q2 23
$372.9M
Q4 22
$469.3M
Q2 22
$395.1M
Total Debt
ASTS
ASTS
SLNO
SLNO
Q4 25
Q3 25
Q2 25
Q4 23
Q3 23
Q2 23
$4.6M
Q4 22
$4.8M
Q2 22
$4.9M
Stockholders' Equity
ASTS
ASTS
SLNO
SLNO
Q4 25
$2.4B
Q3 25
$1.6B
$494.8M
Q2 25
$240.1M
Q4 23
$213.6M
Q3 23
$287.2M
Q2 23
$335.9M
Q4 22
$359.8M
Q2 22
$310.3M
Total Assets
ASTS
ASTS
SLNO
SLNO
Q4 25
$5.0B
Q3 25
$2.6B
$599.9M
Q2 25
$332.3M
Q4 23
$360.9M
Q3 23
$402.1M
Q2 23
$408.5M
Q4 22
$438.4M
Q2 22
$384.9M
Debt / Equity
ASTS
ASTS
SLNO
SLNO
Q4 25
Q3 25
Q2 25
Q4 23
Q3 23
Q2 23
0.01×
Q4 22
0.01×
Q2 22
0.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTS
ASTS
SLNO
SLNO
Operating Cash FlowLast quarter
$65.0M
$43.5M
Free Cash FlowOCF − Capex
$-330.7M
$43.5M
FCF MarginFCF / Revenue
-609.0%
65.8%
Capex IntensityCapex / Revenue
728.7%
0.0%
Cash ConversionOCF / Net Profit
1.67×
TTM Free Cash FlowTrailing 4 quarters
$-790.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTS
ASTS
SLNO
SLNO
Q4 25
$65.0M
Q3 25
$-64.5M
$43.5M
Q2 25
$-12.6M
Q4 23
$-24.9M
Q3 23
$-36.1M
Q2 23
$-50.3M
Q4 22
$-35.0M
Q2 22
$-41.0M
Free Cash Flow
ASTS
ASTS
SLNO
SLNO
Q4 25
$-330.7M
Q3 25
$-302.9M
$43.5M
Q2 25
$-12.6M
Q4 23
$-47.2M
Q3 23
$-109.5M
Q2 23
$-57.8M
Q4 22
$-46.5M
Q2 22
$-69.9M
FCF Margin
ASTS
ASTS
SLNO
SLNO
Q4 25
-609.0%
Q3 25
-2055.0%
65.8%
Q2 25
-38.6%
Q4 23
Q3 23
Q2 23
Q4 22
4647400.0%
Q2 22
-962.8%
Capex Intensity
ASTS
ASTS
SLNO
SLNO
Q4 25
728.7%
Q3 25
1617.6%
0.0%
Q2 25
0.0%
Q4 23
Q3 23
Q2 23
Q4 22
-1143400.0%
Q2 22
398.4%
Cash Conversion
ASTS
ASTS
SLNO
SLNO
Q4 25
Q3 25
1.67×
Q2 25
Q4 23
Q3 23
Q2 23
Q4 22
Q2 22

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTS
ASTS

Products$44.4M82%
Other$7.8M14%
Sat Co$2.1M4%

SLNO
SLNO

Segment breakdown not available.

Related Comparisons